MICHELLE HALL: Open Payments
NPI 1073768545 · SUWANEE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,367 in 69 payments from 23 companies in 2025. Trend: 2023 $1,317 · 2024 $1,929 · 2025 $1,367
Food & beverage: $1,335Education: $32
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $235 |
| Astellas Pharma US Inc | 14 | $229 |
| Boston Scientific Corporation | 6 | $183 |
| Sumitomo Pharma America, Inc. | 4 | $95 |
| PFIZER INC. | 4 | $74 |
| ABBVIE INC. | 3 | $57 |
| Abbott Laboratories | 3 | $55 |
| Amgen Inc. | 3 | $50 |
| Lilly USA, LLC | 3 | $50 |
| Biogen, Inc. | 2 | $49 |
Products named: Veozah, Wegovy, WaveWriter Alpha Prime 16, GEMTESA, FREESTYLE LIBRE 3, LEQEMBI, XIFAXAN, VRAYLAR.
Industry payments across GA — which companies pay providers there.
